<DOC>
	<DOCNO>NCT01820572</DOCNO>
	<brief_summary>The primary purpose assess benefit risk change Cyclosporine Tacrolimus Belatacept 6-60 month kidney transplant .</brief_summary>
	<brief_title>A Study Maintenance Kidney Transplant Recipients Following Conversion Nulojix® ( Belatacept ) -Based</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman , age 1875 inclusive Adult recipient renal allograft live donor decease donor 660 month prior enrollment Receiving stable ( ≥1 month ) regimen Calcineurin inhibitor ( CNI ) [ Cyclosporine A ( CsA ) Tacrolimus ( TAC ) ] Mycophenolate mofetil ( MMF ) Enteric Coated Mycophenolate Sodium ( ECMPS ) /Mycophenolic acid ( MPA ) , corticosteroid Stable renal function 12 week prior enrollment without new onset proteinuria Calculated glomerular filtration rate ( cGFR ) ≥30 ≤75 mL/min/1.73 m2 [ Modification Diet Renal Disease study ( MDRD ) 4formula ] Recipients EpsteinBarr virus ( EBV ) serostatus negative unknown History acute rejection ( AR ) within 3 month prior enrollment History antibody mediate rejection Positive Tcell lymphocytotoxic cross match Proteinuria &gt; 1 g/day &gt; 0.5 g/day diabetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>